Japan invents drug for Ebola Japan is ready to offer its unapproved drug against the deadly Ebola virus

ANKARA (AA) – Japan announced that it has developed a drug for the Ebola virus and are ready to offer the unapproved drug to countries hit by the virus.

Government Spokesman Yoshihide Suga stated in a press conference Monday that the drug, which was invented by a Japanese private company, is at the testing stage. Suga added that if the World Health Organization (WHO) requests, they can send the medicine to countries that have been hit by the virus.

The company pointed out they have medicine to treat more than 20,000 people.

“I am informed that medical professionals could make a request for T-705 in an emergency even before a decision (on approval) by the WHO,” said Suga.

Meanwhile, Japan’s Fujifilm Holdings Corp, announced that they have received an order for the drug abroad, but failed to confirm the quantity or the origin of the request for the drug.

It was also claimed by the company that their drug was developed as a pill, making it more advantageous than the U.S.’ unapproved serum that saved two general practitioners last week in the U.S.

According to the WHO, the Ebola virus has killed at least 1,350 people in West Africa since February.

Ebola, a contagious disease for which there is no known treatment or cure, has claimed hundreds of lives in Sierra Leone, Guinea and Liberia.

The tropical fever, which first appeared in 1976 in Sudan and the Democratic Republic of Congo, can be transmitted to humans from wild animals.

It also reportedly spreads through contact with the bodily fluids of infected persons or of those who have died of the disease.


© 2014, Tutku Şenen . All rights reserved. – The views expressed here are purely those of the author and not necessarily those of the publishers. – Newstime Africa content cannot be reproduced in any form – electronic or print – without prior consent of the Publishers. Copyright infringement will be pursued and perpetrators prosecuted.

10,512 total views, 3 views today

Leave a Reply

Your email address will not be published. Required fields are marked *